Catherine Wall © ECCO |
The low-residue diet has been a short-term dietary strategy to help reduce the symptoms of active Crohn’s Disease and Ulcerative Colitis for at least the last half century. A longer term low-residue diet is also considered appropriate for a subset of patients with intestinal strictures [1], although the evidence to support this recommendation is limited and the type (fibrotic, inflammatory or both), severity (length of stricture and diameter of the bowel lumen), number of strictures and functional properties of certain foods likely impact tolerance of foods [1].
What constitutes a low-residue diet? The phrases “low residue”, “low fibre” and “low roughage” are often used interchangeably in clinical practice, but they are not synonyms.
What is the evidence for using a low-residue or low-fibre diet in active IBD? There is limited evidence to support the theory that a low-residue diet during active IBD is associated with reduced symptoms [3]. Patients often restrict dietary intake during a flare due to inflammation-associated anorexia [4] and, anecdotally, patients associate eating with abdominal pain and bowel motions. A randomised controlled trial of a low-fibre diet compared to an unrestricted diet in 71 patients with mostly (n=58) active Crohn’s Disease found no difference in disease activity or functional symptoms between the groups [5]. This suggests that a strict low-fibre diet is not usually necessary to manage symptoms of active disease.
The currently recommended dietary and nutrition treatments for active Crohn’s Disease are fibre free (e.g. exclusive enteral nutrition) or low in insoluble fibre (e.g. partial enteral nutrition with an exclusion diet) but are not low residue as they often contain dairy proteins. Exclusive or partial enteral nutrition with a dairy protein formula is the most commonly used treatment [6]. All diet and nutrition treatments alter the gut microbiome composition and function in some capacity, and it is hypothesised that it is this mechanism, rather than reduction in faecal bulk, which reduces IBD symptoms and gut inflammation.
Evidence against long-term low-residue diets Patients with IBD consistently eat less fibre than the general population [7] and less than recommended dietary guidelines for the prevention of diseases such as cardiovascular disease and bowel cancer [7]. Recent evidence suggests that consuming adequate fibre, or types of fibre, may be important in promoting maintenance of remission. A large dietary survey of 1130 patients with Crohn’s Disease found that patients in the highest quartile of fibre intake were less likely to have a flare within the six-month follow-up period (adjusted odds ratio 0.58; 95% CI 0.37–0.90) [8]. In patients with a normal ileal pouch-anal anastomosis (n=39), low consumption of fruit (<1.45 servings per day) was associated with development of pouchitis within 12 months (log rank test, p=0.02) while higher consumption of fruit was associated with greater pouch microbial diversity [9]. A high-fibre, low-fat diet was recently compared with an improved standard American diet (higher fibre than a usual American diet) in a randomised, cross-over intervention study in 17 patients with mild or inactive Ulcerative Colitis [10]. The high-fibre diet was well tolerated by patients, reduced markers of inflammation (C-reactive protein) and promoted a favourable gut microbiome composition, including increased abundance of the butyrate-producing bacterium Faecalibacterium prausnitzii. Conversely, supplemental fibre has not consistently been found to improve disease inflammation [11]. A limitation of many of the fibre supplement studies is that background dietary intake is not controlled or assessed. Fibre in a whole food form also comes with many other nutrients (e.g. vitamins, minerals and phytochemicals) that likely confer anti-inflammatory and metabolic benefits.
Broadly, the current evidence suggests that a diet containing adequate fibre (25–30 g per day) may positively alter the gut microbiome, reduce markers of inflammation and promote maintenance of remission, so it should be recommended to most IBD patients.
Practical tips for clinicians: